Unity Biotechnology, Inc. financial data

Symbol
UBX on Nasdaq
Industry
Pharmaceutical Preparations
Location
285 East Grand Avenue, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Cenexys, Inc. (to 7/15/2013), Forge Inc (to 5/5/2009)
Latest financial report
10-Q - Q3 2024 - Nov 4, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 456 % +7.85%
Debt-to-equity 161 % +24%
Return On Equity -101 % -5.15%
Return On Assets -38.9 % +7.43%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16.9M shares +15.3%
Common Stock, Shares, Outstanding 16.9M shares +15.3%
Entity Public Float 34.1M USD +4.81%
Common Stock, Value, Issued 2K USD +100%
Weighted Average Number of Shares Outstanding, Basic 16.8M shares +15.4%
Weighted Average Number of Shares Outstanding, Diluted 16.8M shares +15.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 13.2M USD -46.1%
General and Administrative Expense 15.6M USD -21.3%
Operating Income (Loss) -28.9M USD +42.3%
Net Income (Loss) Attributable to Parent -21.9M USD +49%
Earnings Per Share, Basic -1.28 USD/shares +33.7%
Earnings Per Share, Diluted -1.28 USD/shares +33.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.9M USD +13%
Marketable Securities, Current 20.1M USD -47.1%
Assets, Current 30.3M USD -38.9%
Property, Plant and Equipment, Net 4.41M USD -16.9%
Operating Lease, Right-of-Use Asset 11.4M USD -16%
Other Assets, Noncurrent 200K USD
Assets 47.1M USD -32%
Accounts Payable, Current 1.8M USD +57%
Accrued Liabilities, Current 5.28M USD +0.34%
Liabilities, Current 8.78M USD +1.75%
Operating Lease, Liability, Noncurrent 20.7M USD -15.3%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 33M USD -20.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 39K USD
Retained Earnings (Accumulated Deficit) -502M USD -4.56%
Stockholders' Equity Attributable to Parent 14.1M USD -49%
Liabilities and Equity 47.1M USD -32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.18M USD +54.2%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -7.19M USD -134%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 16.9M shares +15.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.4M USD -221%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.79M USD +11.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 110M USD +9.33%
Deferred Tax Assets, Gross 114M USD +7.33%
Operating Lease, Liability 24.4M USD -12.1%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -21.8M USD +49%
Lessee, Operating Lease, Liability, to be Paid 28.6M USD -14.7%
Property, Plant and Equipment, Gross 14.3M USD -30.3%
Operating Lease, Liability, Current 3.73M USD +11%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.29M USD +3.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.12M USD +3.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.12M USD -27.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.46M USD +3.22%
Deferred Tax Assets, Operating Loss Carryforwards 81.1M USD +10.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 17.5M USD -0.84%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.63M USD +3.23%
Operating Lease, Payments 1.2M USD -29.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 227K USD -31%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 4.46M USD -46.9%
Interest Expense 1.45M USD -61.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%